Videos

In the first part of a two-part interview, Nina Kottler, M.D. offers insights and perspective on the recently issued guidance from the FDA on AI-enabled devices and how it may impact developers in the radiology field.

In a recent interview, Phillip Kuo, M.D., discussed the impact of newer anti-amyloid antibody therapies for Alzheimer’s disease upon recently issued appropriate use criteria (AUC) for amyloid positron emission tomography (PET) imaging as well as the incorporation of tau PET into the AUC for patients with mild cognitive impairment.

In a recent interview, Arlene Sussman, M.D., discussed her experience in leading vRad’s teleradiology breast imaging service, how to foster personalized care in breast cancer screening, utilizing AI to help mitigate daunting worklists and improving access to subspecialty care.

In the third part of a three-part interview from the recent RSNA conference, Mark Traill, M.D., discusses the potential of image-based risk assessment artificial intelligence (AI) algorithms in bolstering adherence to screening protocols for women at high risk for breast cancer.

In the second part of a three-part interview from the recent RSNA conference, Mark Traill, M.D., emphasizes patience and monitoring with the assessment of AI to ensure optimal use of the technology to help ease the strain of increasing breast imaging volume.

In the first of a three-part interview from the recent RSNA conference, Mark Traill, M.D., discusses current challenges in breast radiology and the potential of AI to help mitigate some of these issues.

In a recent interview at the RSNA conference, Raj Chopra, MD shared his insights on the continued rise of cyberattacks, the impact of these attacks in radiology and keys to prevention and effectively responding to such events.

In an interview at the RSNA conference, Sundus Lateef, MD, discussed the rise of silicosis and associated CT findings in a recent study of engineered stone countertop workers.

In a recent interview, Sarah Friedewald, MD, discussed new study findings for an adjunctive AI software for digital breast tomosynthesis (DBT) that revealed nearly equivalent sensitivity and specificity rates for breast cancer across a diverse cohort.

In a recent interview at the RSNA conference, Shadpour Demehri, MD and Kamyar Moradi, MD discussed new brain MRI research findings that demonstrated a link between increased dementia risk and sarcopenia with the temporalis muscle.

Slower aperiodic activity on magnetoencephalopathy may be associated with higher post-concussion symptomatology in high-school football players, according to new research to be presented at the Radiological Society of North America (RSNA) conference.

In a recent interview, Richard Duszak, MD, discussed new study findings that showed over nine percent annual increases in ultrasound, CT and MRI interpretation by office-based non-physician practitioners (NPPs) between 2013 and 2022.

In an interview, SNMMI president Cathy Cutler, PhD, discussed the impact of the recent CMS decision to unbundle reimbursement for diagnostic radiopharmaceuticals costing above $630 a day, calling it a “game changer” decision that will benefit patients, physicians, and the development of new radiopharmaceutical agents.

In a recent interview, Stamatia Destounis, M.D., discussed the impact of national breast density notification for mammography reports and key considerations with staffing and ongoing education for patients, staff and referring providers on the merits of supplemental breast imaging.

Key opinion leaders offer insights on closing knowledge gaps and highlight crucial factors for physicians to consider when interpreting gallium-based PET imaging results in clinical practice.

Medical experts address challenges and propose solutions for inter-readability concerns in nuclear medicine, particularly focusing on strategies to overcome the scarcity of specialized readers.

In a recent interview, Bridget Koontz, M.D., discussed the capability of the PET imaging agent 18F-flotufolastat for diagnosing post-prostatectomy recurrence of prostate cancer in patients with PSA values less than 1 ng/mL, based on research presented at the American Society for Radiation Oncology (ASTRO) conference.

Key opinion leaders explore the significance of interdisciplinary collaboration in prostate cancer management, with a focus on how PSMA PET imaging enhances decision-making processes within multidisciplinary care teams.

Jaideep Sohi, MD, and Jeremie Calais, MD, conduct a comparative assessment of gallium-based and non-gallium-based imaging agents for their efficacy in detecting and characterizing oligometastatic prostate cancer.

Medical experts conduct a comparative assessment of gallium-based and non-gallium-based imaging agents to determine their efficacy in detecting and characterizing oligometastatic prostate cancer.

Jaideep Sohi, MD, and Jeremie Calais, MD, explore the complexities of managing oligometastatic disease, emphasizing the critical role of accurately assessing lesion counts, metastatic spread, and disease thresholds in optimizing clinical outcomes.

Key opinion leaders examine the role of advanced imaging agents, particularly PSMA PET and other radiotracers, in identifying and defining oligometastatic disease in patients with prostate cancer.

Experts in radiology imaging evaluate the impact and efficacy of PSMA PET in improving early detection methods and refining prostate cancer staging processes.

Key opinion leaders analyze the advantages of integrating PSMA PET imaging with traditional imaging techniques to enhance prostate cancer management and treatment strategies.

Jaideep Sohi, MD, and Jeremie Calais, MD, examine the comparative merits of PSMA PET and Gallium-Based PET while exploring the application of NCCN Guidelines in prostate cancer imaging protocols.

In a recent interview, Soroush Rais-Bahrami, M.D., discussed key findings from a post-hoc subgroup analysis of the SPOTLIGHT trial that examined the use of the PET imaging agent 18F-flotufolastat (Posluma) in African American men.

In a recent interview at the SNMMI conference, David Gauden, D.Phil, discussed key findings from new research evaluating the use of the PET radiotracer 18F-flotufolastat in patients with primary prostate cancer (PCa) and men with biochemical recurrence of PCa.

In an interview at the SNMMI 2024 conference, Oliver Sartor, M.D. discussed key findings from new award-winning research evaluating the potential of Pluvicto in treating patients with taxane-naïve metastatic castration-resistant prostate cancer (mCRPC).